KapaVax - Model VXD005 -Inactivated LPS-Null (Endotoxin Free) Whole-Cell Acinetobacter Baumannii Vaccine

Active principle: Inactivated LPS-null (endotoxin free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae.

Stage: Preclinical development

Indication: Raise active immunity against 100% of circulating strains of each Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae in the population in hospitals or the community at risk of developing infections by these bacteria.

Highlights: First multivalent vaccine candidate of Vaxdyn’s technological platform. First proof of principle in humans expected in 2023. Product powered by the global accelerator CARB-X.